Trusted Resource for Clinical Trials, Protocols & Progress
Managing Unexpected Toxicity in Phase 2 Studies How to Manage Unexpected Toxicity in Phase 2 Clinical Trials Introduction Phase 2 clinical trials often provide the first extended exposure of an investigational drug to patients with the target disease. While early safety has been assessed in Phase 1, it is in Phase 2 that new or…
Read More “Managing Unexpected Toxicity in Phase 2 Studies” »
Biomarker Integration in Phase 1: Validated, Exploratory, and Surrogate Endpoints Biomarker Integration in Phase 1: Validated, Exploratory, and Surrogate Endpoints Introduction Biomarkers have become a cornerstone of modern drug development, especially in early-phase clinical trials. In Phase 1 studies, where the primary focus is on safety and pharmacokinetics (PK), biomarkers serve as crucial tools to…
Read More “Biomarker Integration in Phase 1: Validated, Exploratory, and Surrogate Endpoints” »
Defining and Tracking Safety Endpoints in Phase 2 Trials How to Define and Track Safety Endpoints in Phase 2 Clinical Trials Introduction In Phase 2 clinical trials, safety remains a core focus alongside efficacy. One of the most structured ways to assess safety is through the use of defined safety endpoints. These are pre-specified metrics…
Read More “Defining and Tracking Safety Endpoints in Phase 2 Trials” »
Analyzing Phase 1 Pharmacokinetics: From Sample to Report Analyzing Phase 1 Pharmacokinetics: From Sample to Report Introduction Pharmacokinetic (PK) analysis is a fundamental component of Phase 1 clinical trials. It provides insight into how a drug is absorbed, distributed, metabolized, and eliminated in humans. This data is essential for determining safe and effective dosing regimens….
Read More “Analyzing Phase 1 Pharmacokinetics: From Sample to Report” »
Handling Adverse Events and Serious Adverse Events (SAEs) How to Handle Adverse Events and Serious Adverse Events (SAEs) in Phase 2 Trials Introduction Adverse events (AEs) and serious adverse events (SAEs) are a core focus of safety monitoring in clinical trials, particularly in Phase 2 where investigational drugs are administered to patients with the target…
Read More “Handling Adverse Events and Serious Adverse Events (SAEs)” »
PK and PD Sampling Strategies in Phase 1: What to Measure and When PK and PD Sampling Strategies in Phase 1: What to Measure and When Introduction One of the most important goals of Phase 1 clinical trials is to understand how a new drug behaves in the human body. This is achieved by studying…
Read More “PK and PD Sampling Strategies in Phase 1: What to Measure and When” »
Role of DSMBs and Ethics Committees in Phase 2 Trials Understanding the Role of DSMBs and Ethics Committees in Phase 2 Clinical Trials Introduction As investigational drugs progress into Phase 2 clinical trials, they are tested in larger patient populations and often for longer periods. This increases both the complexity and the ethical responsibilities of…
Read More “Role of DSMBs and Ethics Committees in Phase 2 Trials” »
Stopping Rules and Dose Limiting Toxicity (DLT) Criteria in Phase 1 Trials Stopping Rules and Dose Limiting Toxicity (DLT) Criteria in Phase 1 Trials Introduction Phase 1 clinical trials aim to evaluate the safety, tolerability, and pharmacokinetics of investigational products, especially in first-in-human (FIH) settings. One of the most critical aspects of early-phase trial design…
Read More “Stopping Rules and Dose Limiting Toxicity (DLT) Criteria in Phase 1 Trials” »
Safety Monitoring Requirements in Phase 2 Trials Safety Monitoring in Phase 2 Trials: Procedures, Responsibilities, and Best Practices Introduction Phase 2 clinical trials mark the transition from safety-focused Phase 1 studies to trials evaluating both efficacy and continued safety in patients. As drugs are tested in larger populations and for longer durations, robust safety monitoring…
Read More “Safety Monitoring Requirements in Phase 2 Trials” »
Adverse Event Monitoring in Phase 1: Definitions, Reporting, and Grading Adverse Event Monitoring in Phase 1: Definitions, Reporting, and Grading Introduction Adverse event (AE) monitoring is at the heart of Phase 1 clinical trials, where the primary objective is to establish the safety and tolerability of a new investigational product (IP). Because participants are often…
Read More “Adverse Event Monitoring in Phase 1: Definitions, Reporting, and Grading” »
